These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 2804373)

  • 1. Heterogeneous phenotypes of platelet and plasma von Willebrand factor in obligatory heterozygotes for severe von Willebrand disease.
    Mannucci PM; Lattuada A; Castaman G; Lombardi R; Colibretti ML; Ciavarella N; Rodeghiero F
    Blood; 1989 Nov; 74(7):2433-6. PubMed ID: 2804373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterogeneity of type I von Willebrand disease: evidence for a subgroup with an abnormal von Willebrand factor.
    Mannucci PM; Lombardi R; Bader R; Vianello L; Federici AB; Solinas S; Mazzucconi MG; Mariani G
    Blood; 1985 Oct; 66(4):796-802. PubMed ID: 3876122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A probable double heterozygous type II von Willebrand's disease with increased ristocetin induced platelet aggregation.
    Kinoshita S; Yoshioka K; Kasahara M; Takamiya O
    Am J Hematol; 1992 Jul; 40(3):192-8. PubMed ID: 1609773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type II H von Willebrand disease: new structural abnormality of plasma and platelet von Willebrand factor in a patient with prolonged bleeding time and borderline levels of ristocetin cofactor activity.
    Federici AB; Mannucci PM; Lombardi R; Lattuada A; Colibretti ML; Dent JA; Zimmerman TS
    Am J Hematol; 1989 Dec; 32(4):287-93. PubMed ID: 2510503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. von Willebrand disease "Vicenza" with larger-than-normal (supranormal) von Willebrand factor multimers.
    Mannucci PM; Lombardi R; Castaman G; Dent JA; Lattuada A; Rodeghiero F; Zimmerman TS
    Blood; 1988 Jan; 71(1):65-70. PubMed ID: 3257148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role for platelet von Willebrand factor in supporting platelet-vessel wall interactions in von Willebrand disease.
    Castillo R; Escolar G; Monteagudo J; Ordinas A; Garrido M; Moia M; Federici AB; Mannucci PM
    Am J Hematol; 1989 Jul; 31(3):153-8. PubMed ID: 2787114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New families with von Willebrand disease type 2M (Vicenza).
    Zieger B; Budde U; Jessat U; Zimmermann R; Simon M; Kätzel R; Sutor AH
    Thromb Res; 1997 Jul; 87(1):57-64. PubMed ID: 9253800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High resolution multimer analysis and the PFA-100 platelet function analyser can detect von Willebrand disease type 2A without a pathological ratio of ristocetin cofactor activity and von Willebrand antigen level.
    Weiss DR; Strasser EF; Ringwald J; Zimmermann R; Eckstein R
    Clin Lab; 2012; 58(11-12):1203-9. PubMed ID: 23289190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma collagen cofactor correlates with von Willebrand factor antigen and ristocetin cofactor but not with bleeding time.
    Aihara M; Kimura A; Chiba Y; Yoshida Y
    Thromb Haemost; 1988 Jun; 59(3):485-90. PubMed ID: 3142084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo experiments indicate that relatively high platelet deposition in von Willebrand's disease 'Vicenza' is caused by normal platelet-VWF levels rather than by high VWF-multimers in plasma.
    d'Alessio PA; Castaman G; Rodeghiero F; de Boer HC; Federici AB; Mannucci PM; de Groot PG; Sixma JJ; Zwaginga JJ
    Thromb Res; 1992 Jan; 65(2):221-8. PubMed ID: 1579897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet von Willebrand factor: an important determinant of the bleeding time in type I von Willebrand's disease.
    Gralnick HR; Rick ME; McKeown LP; Williams SB; Parker RI; Maisonneuve P; Jenneau C; Sultan Y
    Blood; 1986 Jul; 68(1):58-61. PubMed ID: 3487361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new von Willebrand variant (type I, New York): increased ristocetin-induced platelet aggregation and plasma von Willebrand factor containing the full range of multimers.
    Weiss HJ; Sussman II
    Blood; 1986 Jul; 68(1):149-56. PubMed ID: 3487353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. von Willebrand factor binds to platelets and induces aggregation in platelet-type but not type IIB von Willebrand disease.
    Miller JL; Kupinski JM; Castella A; Ruggeri ZM
    J Clin Invest; 1983 Nov; 72(5):1532-42. PubMed ID: 6415113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of von Willebrand factor and factor VIIIC in patients with severe von Willebrand disease (type 3 VWD): estimation of the rate of factor VIIIC synthesis. Cooperative Study Groups.
    Menache D; Aronson DL; Darr F; Montgomery RR; Gill JC; Kessler CM; Lusher JM; Phatak PD; Shapiro AD; Thompson AR; White GC
    Br J Haematol; 1996 Sep; 94(4):740-5. PubMed ID: 8826903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. von Willebrand's disease characterized by increased ristocetin sensitivity and the presence of all von Willebrand factor multimers in plasma.
    Holmberg L; Berntorp E; Donnér M; Nilsson IM
    Blood; 1986 Sep; 68(3):668-72. PubMed ID: 3488775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel von Willebrand factor mutation (I1372S) associated with type 2B-like von Willebrand disease: an elusive phenotype and a difficult diagnosis.
    Casonato A; Sartorello F; Pontara E; Gallinaro L; Bertomoro A; Grazia Cattini M; Daidone V; Szukowska M; Pagnan A
    Thromb Haemost; 2007 Dec; 98(6):1182-7. PubMed ID: 18064311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemostasis in patients with severe von Willebrand disease improves after normal platelet transfusion and normalizes with further correction of the plasma defect.
    Castillo R; Escolar G; Monteagudo J; Aznar-Salatti J; Reverter JC; Ordinas A
    Transfusion; 1997 Aug; 37(8):785-90. PubMed ID: 9280321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective study of low-dose ristocetin-induced platelet aggregation to identify type 2B von Willebrand disease (VWD) and platelet-type VWD in children.
    Frontroth JP; Hepner M; Sciuccati G; Feliú Torres A; Pieroni G; Bonduel M
    Thromb Haemost; 2010 Dec; 104(6):1158-65. PubMed ID: 20941465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type 2M von Willebrand disease: F606I and I662F mutations in the glycoprotein Ib binding domain selectively impair ristocetin- but not botrocetin-mediated binding of von Willebrand factor to platelets.
    Hillery CA; Mancuso DJ; Evan Sadler J; Ponder JW; Jozwiak MA; Christopherson PA; Cox Gill J; Paul Scott J; Montgomery RR
    Blood; 1998 Mar; 91(5):1572-81. PubMed ID: 9473222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.